What is the risk of tumor lysis syndrome and how can it be treated?
Clolar is a chemotherapeutic agent with a rapid onset of action. Administration of Clolar results in a rapid reduction in peripheral leukemia cells. Therefore, all patients should be watched closely for early signs and symptoms of tumor lysis syndrome (such as nausea, vomiting, diarrhea, muscle cramps, arrhythmias, hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia) that could develop into SIRS/capillary leak syndrome (e.g. tachypnea, tachycardia, hypotension, and pulmonary edema). Clolar should be discontinued immediately in the event of clinically significant signs and symptoms of SIRS or capillary leak, either of which can be fatal, and the use of steroids, diuretics and albumin considered. Clinicians are encouraged to give continuous IV fluids throughout the 5 days of Clolar administration to reduce the effects of tumor lysis and other adverse events. If signs and symptoms of tumor lysis syndrome are anticipated or manifest, aggressive hydration and hypouricemic agent
